Side-by-side comparison of AI visibility scores, market position, and capabilities
Patient scheduling and engagement platform for multi-specialty practices, combining intelligent scheduling, reminders, and digital intake. Franklin TN, raised $41M+.
Relatient is a patient engagement and scheduling company that provides healthcare providers with an integrated platform for scheduling automation, appointment reminders, digital check-in, and patient communication. Founded in 2013 and headquartered in Franklin, Tennessee, Relatient has raised more than $41 million and serves health systems, hospital outpatient departments, and multi-specialty physician groups across the United States. The company's Dash platform delivers intelligent self-scheduling, automated reminder workflows, digital intake forms, and post-visit survey capabilities through a single system that integrates with major EHR and practice management software.\n\nRelatiently's Dash scheduling platform is built around intelligent appointment matching, directing patients to the right provider, location, and appointment type based on clinical criteria and insurance requirements rather than offering a simple open calendar view. This smart scheduling approach reduces scheduling errors and the downstream revenue cycle problems they cause, while improving the patient experience by eliminating the friction of calling and navigating phone trees. The platform supports scheduling across complex multi-provider, multi-location organizations where routing rules are an important operational requirement.\n\nRelatiently competes in a market that has grown significantly as providers recognize the revenue and operational impact of patient access optimization. The company differentiates through its depth of EHR integration, its focus on enterprise multi-specialty environments, and its comprehensive approach to the full patient engagement lifecycle from first contact through post-visit follow-up. Relatient's combination of scheduling intelligence and communication automation serves as an integrated patient access solution for organizations that need more than basic reminder tools.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.